7828 related articles for article (PubMed ID: 12068386)
1. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
2. Histamine in cancer immunotherapy: a preclinical background.
Hellstrand K
Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
[TBL] [Abstract][Full Text] [Related]
3. New applications of cancer immunotherapy.
Agarwala SS
Semin Oncol; 2002 Jun; 29(3 Suppl 7):1-4. PubMed ID: 12068381
[No Abstract] [Full Text] [Related]
4. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with natural killer cells.
Herberman RB
Semin Oncol; 2002 Jun; 29(3 Suppl 7):27-30. PubMed ID: 12068385
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in the management of renal cell carcinoma.
Glaspy JA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):41-6. PubMed ID: 12068388
[TBL] [Abstract][Full Text] [Related]
7. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
Stadtmauer EA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
[TBL] [Abstract][Full Text] [Related]
8. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
9. Histamine: a novel approach to cancer immunotherapy.
Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2: clinical applications.
Atkins MB
Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
[TBL] [Abstract][Full Text] [Related]
11. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
12. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
Brune M; Hansson M; Mellqvist UH; Hermodsson S; Hellstrand K
Eur J Haematol; 1996 Oct; 57(4):312-9. PubMed ID: 8982295
[TBL] [Abstract][Full Text] [Related]
13. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
Agarwala SS; Sabbagh MH
Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
[No Abstract] [Full Text] [Related]
15. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
[TBL] [Abstract][Full Text] [Related]
16. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
17. Interaction of chemotherapy and biological response modifiers in the treatment of melanoma.
Anderson CM; Buzaid AC; Grimm EA
Cancer Treat Res; 1996; 87():357-80. PubMed ID: 8886461
[No Abstract] [Full Text] [Related]
18. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant histamine in cancer immunotherapy.
Hellstrand K; Hansson M; Hermodsson S
Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269
[TBL] [Abstract][Full Text] [Related]
20. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]